Clene (CLNN) Stock Price

Clene Price

NASDAQ·CLOSED
3.77
​
Market closed

Revenue at Clene has contracted by 0.6% per year over the past 5 years to 200,000.00 USD. For Clene, the net margin of -13,086.5% is down versus -1,347.2% a few years ago. The consensus 12-month price target for Clene is 5.10 USD, about 35.3% above where the stock trades today. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus.

Clene stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene business model & stock analysis

Clene Inc develops therapeutic products for neurodegenerative diseases, focusing on targeting energetic failure as a root cause. Its primary product CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by enhancing energy production and utilization. The company also develops CNM-ZnAg, a spectrum antiviral and antibacterial agent containing zinc and silver ions for infectious disease treatment and immune support, and CNM-AgZn17, a gel polymer suspension of zinc and silver for wound healing and infectious disease management. These products are intended for clinical development and eventual commercialization in the pharmaceutical market. Clene's target customers are patients suffering from neurodegenerative diseases and infectious conditions requiring antiviral, antibacterial, or wound healing solutions. The company's products aim to address unmet medical needs in these therapeutic areas by leveraging innovative nanocrystal and ion-based technologies. The firm operates within the biopharmaceutical sector, developing treatments that focus on cellular energy processes to provide neuroprotection and remyelination. The company generates revenue through the development and potential future commercialization of its drug candidates. CNM-Au8 targets neurodegenerative diseases by addressing energetic failure, while CNM-ZnAg and CNM-AgZn17 focus on infectious disease treatment and wound healing applications. These products are in clinical development stages, with the company seeking to advance them toward regulatory approval and market entry.

Frequently asked questions about Clene

Analysts currently set an average price target of 5.10 USD for the Clene stock (median: 5.10 USD), implying +24.4 % versus the latest price. The consensus is based on 11 analyst ratings.

11 analysts currently rate the Clene stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Clene to generate revenue of 276,250.00 USD and earnings per share of -1.19 USD.

Converted at the current exchange rate, the Clene share trades at 3.36 EUR (3.77 USD).

The Clene share (CLNN) is listed on 2 stock exchanges, including: NASDAQ (CLNN), Frankfurt (84C.F).

The expected revenue of Clene is 276,250.00 USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Clene is -11.74 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Clene is currently -3.17. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Clene stock.

The price-to-sales ratio (P/S) of Clene is currently 134.54. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Clene stock.

The Eulerpool Quality Score for Clene is 4/10.

The ISIN of Clene is US1856342019. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Clene is A2QE9Y. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Clene is CLNN. The ticker symbol is used to trade Clene shares on the stock exchange.

Fair ValueTerminal
3.58 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
2,666.67 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website clene.com
Currency
USD
Initial public offering
Aug 27, 2018
ISIN
US1856342019
Cusip
185634102
Market capitalization
40.90 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-3.17
P/Ee 2027
-2.29
P/Ee 2028
1.65
P/Ee 2029
0.60
P/Ee 2030
0.37
P/Se
134.54
EV/EBIT
—
P/B Ratio
3.05
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-641.34 %
Last updated Nov 6, 2026, 3:39 AM

Clene Peer Group

Clene Ticker

FRANKFURT · 84C.FNASDAQ · CLNN

All fundamentals and in-depth analysis of Clene

Our stock analysis for Clene stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Clene. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.